Eli Lilly and Company (LLY) on Decifer

Decifer ranks LLY number 111 of 276 tracked names on durable business quality.

Why it ranks here

• It earns strong returns on the money it puts to work, around 30% and those returns have been improving.
• Revenue is growing about 45% a year, profits grew 96% over the past year, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• It is riding an active market tailwind and has the balance sheet to fund its growth.
• It is not watering down its owners with new shares and it returns cash to shareholders.
• Its profit margin and growth are both unusually high right now compared to its own history, the kind of combination that often fades once conditions normalize.
• Returns around 30% and revenue growing about 45% a year are exceptional, but the margin and growth mix often fades and it holds no stated role in our worldview.

The current read

The evidence on LLY points in two directions at once: a live market force supports this name through its theme connection, while fresh news: Jim Cramer: Eli Lilly Is A 'Good Company,' But Doesn't 'Really Care For' This Quantum Stock. Until one side gives way, treat the picture as unresolved rather than a clean story.

Themes

• GLP-1 & Metabolic Health: Eli Lilly's Zepbound (tirzepatide) and Mounjaro are leading approved GLP-1 drugs. US Zepbound revenue grew 122% year-over-year in Q4 2025 per Lilly investor relations. Primary pharmaceutical revenue from obesity and diabetes treatment.

Read the full LLY research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.